Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:550 (4 March), doi:10.1136/bmj.332.7540.550
| The first 150 words of the full text of this article appear below. |
EDITORBuscemi et al in their meta-analysis report that melatonin is ineffective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction such as jet lag or shift work.1 The published reports in this domain certainly show some inconsistency, and now there is inconsistency in the meta-analyses.2 Numerous published studies, mostly with a positive result, have not been included, even the first controlled jet lag trial, published in the BMJ.3
Buscemi et al may have done a disservice to people who do benefit from melatonin and may in consequence be denied access (in the United Kingdom) to this prescription-only medication. For example, the authors do not mention the importance of melatonin in blind sleep disorder and delayed sleep phase syndrome. Some of the data have appeared previously in a report from the Agency for Healthcare Research and Quality,3 where benefits for delayed sleep phase syndrome were identified.4
| |||||||||||
Josephine Arendt, professor of endocrinology, emeritus
Centre for Chronobiology, School of Biomedical and Molecular Sciences, University of Surrey, Guildford, Surrey GU2 7XH Arendtjo@aol.com
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care